Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
Study Purpose
The purpose of this study is to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 18 Years - 50 Years |
Gender | All |
Inclusion Criteria:
- - Able to understand and communicate with the investigator, willing and capable to comply with all study procedures, and provide written signed and dated informed consent (personally or by a witness) before any assessment is performed.
- - Aged 18 to 40 years inclusive.
- - New-onset plaque psoriasis with appearance of the first psoriasis plaques within the last 12 months before randomization and naïve to any systemic treatment and phototherapy (Arms A1, A2 and Arm B1) - Chronic plaque psoriasis with appearance of the first psoriasis symptoms 5 years or longer and intolerance or inadequate response to phototherapy or any systemic treatment including biologicals, except for IL-17A inhibitors (Arm C1 and Arm C2) - Moderate to severe plaque psoriasis defined at screening and baseline by PASI ≥ 10, and body surface area (BSA) ≥ 10%, and investigator's global assessment (IGA mod 2011) ≥ 3.
Exclusion Criteria:
- - Forms of psoriasis other than plaque-type (e.g., pustular, erythrodermic, guttate, light sensitive, and drug induced) - Ongoing use of prohibited treatments.
- - Previous treatment with phototherapy or any systemic treatment.
- - Pregnant or nursing (lactating) women.
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT03020199 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 4 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Novartis Pharmaceuticals |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
N/A |
Principal Investigator Affiliation | N/A |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
Overall Status | Recruiting |
Countries | Argentina, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Germany, Hungary, Norway, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Plaque Psoriasis |
The overall study population (Main Study and Mechanistic Sub-study) will consist of a total of 205 male and female patients aged between 18 and 40 years inclusive. Main Study The Main Study will be conducted in patients with new-onset moderate to severe plaque psoriasis not previously treated with any systemic treatment or phototherapy. A total of 160 patients will be randomized to Arm A1 or Arm B1 in approximately 50 sites worldwide. Since a maximum screening failure rate of 20% is expected, approximately 200 patients will be screened. Mechanistic Sub-study Any patient who consents can participate in the Mechanistic Sub-study. Patients with new-onset plaque psoriasis will be randomized to Arm A1b, Arm A2, or Arm B1b, those with chronic plaque psoriasis will be randomized to Arm C1 and Arm C2 (15 patients each). For Arm A1b or Arm B1b, the first 15 patients will be included on a first come first serve basis. Safety assessments :Physical examination, Vital signs, Height and body weight, Laboratory evaluations (hematology, clinical chemistry, high-sensitivity C-reactive protein), Electrocardiogram, Pregnancy, Adverse events. Data Analysis The primary efficacy variable is the proportion of patients who achieve PASI 90 at Week 52. The analysis for the primary objective will be based on the full analysis set. For the primary analysis, the following hypothesis testing will be performed: H01: psec = pnbUVB versus HA1: psec ≠ pnbUVB The primary analysis method for PASI 90 response at Week 52 will use an exact logistic regression model with treatment as an explanatory variable and baseline PASI score as covariate. The key secondary variable is the proportion of all randomized patients who achieve PASI 90 at Week 104. In order to reduce selection bias, all patients who do not achieve PASI 90 at Week 52 will also be included in the analysis at Week 104 using the PASI improvement obtained at Week 104 only. For the key secondary analysis, the following hypothesis testing will be performed: H02: p*sec = p*nbUVB versus HA2: p*sec ≠ p*nbUVB
Arms
Experimental: A1
80 patients (65 in Arm A1a and 15 in Arm A1b) with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 48 inclusive.
Active Comparator: B1
80 patients (65 in Arm B1a and 15 in Arm B1b) with new-onset psoriasis will receive 1 or 2 cycles of nb-UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 will not receive a second treatment cycle).Only during the first 4 weeks of each cycle, nb-UVB treatment should be applied in combination with topical calcipotriol 50 μg/g and betamethasone 0.5 mg/g.
Experimental: A2
secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
Experimental: C1
secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 48 inclusive (last dose administered at Week 48)
Experimental: C2
secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
Interventions
Biological: - Secukinumab
Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL.
Radiation: - nbUVB
Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application will be performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face is recommended
Biological: - Secukinumab
Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
Biological: - Secukinumab
Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
Biological: - Secukinumab
Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
Drug: - Calcipotriol
Its a topical treatment for Psoriasis. the concentration it is used is 50mcg/g
Drug: - Betamethasone
this is topical cream which is used in 0.5mg/g concentration
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
International Sites
Status
Completed
Address
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, 1181
Status
Completed
Address
Novartis Investigative Site
Buenos Aires, , C1425DKG
Status
Active, not recruiting
Address
Novartis Investigative Site
Pleven, , 5800
Status
Completed
Address
Novartis Investigative Site
Plovdiv, , 4002
Status
Completed
Address
Novartis Investigative Site
Sofia, , 1407
Status
Withdrawn
Address
Novartis Investigative Site
Sofia, , 1431
Status
Active, not recruiting
Address
Novartis Investigative Site
Sofia, , 1632
Status
Withdrawn
Address
Novartis Investigative Site
Surrey, British Columbia, V3V 0C6
Status
Recruiting
Address
Novartis Investigative Site
Halifax, Nova Scotia, B3H 1Z2
Status
Completed
Address
Novartis Investigative Site
Markham, Ontario, L3P 1X2
Status
Active, not recruiting
Address
Novartis Investigative Site
Sudbury, Ontario, P3C 1X8
Status
Withdrawn
Address
Novartis Investigative Site
Toronto, Ontario, M3H 5Y8
Status
Withdrawn
Address
Novartis Investigative Site
Brno, , 656 91
Status
Withdrawn
Address
Novartis Investigative Site
Pardubice, , 532 03
Status
Active, not recruiting
Address
Novartis Investigative Site
Aarhus, , 8000
Status
Withdrawn
Address
Novartis Investigative Site
Hellerup, , 2900
Status
Completed
Address
Novartis Investigative Site
Tallinn, , 10138
Status
Active, not recruiting
Address
Novartis Investigative Site
Tallinn, , 13419
Status
Active, not recruiting
Address
Novartis Investigative Site
Tartu, , 51014
Status
Completed
Address
Novartis Investigative Site
Tampere, , 33100
Status
Completed
Address
Novartis Investigative Site
Turku, , FIN-20100
Status
Withdrawn
Address
Novartis Investigative Site
Bad Bentheim, , 48455
Status
Completed
Address
Novartis Investigative Site
Berlin, , 10789
Status
Completed
Address
Novartis Investigative Site
Berlin, , 13353
Status
Active, not recruiting
Address
Novartis Investigative Site
Erlangen, , 91054
Status
Active, not recruiting
Address
Novartis Investigative Site
Frankfurt, , 60590
Status
Withdrawn
Address
Novartis Investigative Site
Luebeck, , 23538
Status
Withdrawn
Address
Novartis Investigative Site
Potsdam, , 14467
Status
Withdrawn
Address
Novartis Investigative Site
Quedlinburg, , 06484
Status
Withdrawn
Address
Novartis Investigative Site
Budapest, , 1137
Status
Withdrawn
Address
Novartis Investigative Site
Gyor, , H-9023
Status
Completed
Address
Novartis Investigative Site
Nyíregyháza, , 4400
Status
Active, not recruiting
Address
Novartis Investigative Site
Szolnok, , 5000
Status
Withdrawn
Address
Novartis Investigative Site
Bergen, , NO-5021
Status
Withdrawn
Address
Novartis Investigative Site
Oslo, , N-0372
Status
Withdrawn
Address
Novartis Investigative Site
Tromsø, , N-9038
Status
Withdrawn
Address
Novartis Investigative Site
Trondheim, , N-7006
Status
Completed
Address
Novartis Investigative Site
Bialystok, , 15-879
Status
Completed
Address
Novartis Investigative Site
Bydgoszcz, , 85-094
Status
Withdrawn
Address
Novartis Investigative Site
Gdansk, , 80 952
Status
Completed
Address
Novartis Investigative Site
Gdansk, , 80-803
Status
Active, not recruiting
Address
Novartis Investigative Site
Krakow, , 31-070
Status
Active, not recruiting
Address
Novartis Investigative Site
Lodz, , 90-436
Status
Active, not recruiting
Address
Novartis Investigative Site
Lodz, , 90-647
Status
Recruiting
Address
Novartis Investigative Site
Lublin, , 20-079
Status
Withdrawn
Address
Novartis Investigative Site
Iasi, , 700401
Status
Withdrawn
Address
Novartis Investigative Site
Badalona, Catalunya, 08916
Status
Completed
Address
Novartis Investigative Site
Barcelona, Catalunya, 08003
Status
Active, not recruiting
Address
Novartis Investigative Site
Barcelona, Catalunya, 08036
Status
Completed
Address
Novartis Investigative Site
Alicante, Comunidad Valenciana, 03010
Status
Completed
Address
Novartis Investigative Site
Valencia, Comunidad Valenciana, 46014
Status
Active, not recruiting
Address
Novartis Investigative Site
Alcorcon, Madrid, 28922
Status
Withdrawn
Address
Novartis Investigative Site
Barcelona, , 08041
Status
Completed
Address
Novartis Investigative Site
Las Palmas de Gran Canaria, , 35010
Status
Withdrawn
Address
Novartis Investigative Site
Madrid, , 28006
Status
Active, not recruiting
Address
Novartis Investigative Site
Madrid, , 28031
Status
Active, not recruiting
Address
Novartis Investigative Site
Madrid, , 28041
Status
Completed
Address
Novartis Investigative Site
Goethenburg, ,
Status
Completed
Address
Novartis Investigative Site
Malmo, , 214 28
Status
Withdrawn
Address
Novartis Investigative Site
Stockholm, , 17176
Status
Withdrawn
Address
Novartis Investigative Site
Geneve, , 1205
Status
Completed
Address
Novartis Investigative Site
Lausanne, , CH-1011
Status
Withdrawn
Address
Novartis Investigative Site
Zuerich, , 8091
Status
Active, not recruiting
Address
Novartis Investigative Site
Bradford, West Yorkshire, BD5 0NA
Status
Active, not recruiting
Address
Novartis Investigative Site
Leeds, West Yorkshire, LS7 4SA
Status
Active, not recruiting
Address
Novartis Investigative Site
London, , SE1 9RT
Status
Completed
Address
Novartis Investigative Site
Salford, , M6 8HD